FDA accepts NDA for Zubsolv

Orexo AB (SSE:ORX) said FDA accepted for review an NDA for Zubsolv buprenorphine/naloxone to treat opioid dependence. The PDUFA date is July 6, 2013. The application was submitted under section 505(b)...